Physician profile
Tri T Nguyen
NPI 1427155829
$16,605.66
in general payments reported to CMS, 2019-2025
73 companies · $2,603 in 2025
The $2,603 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,814 · 2020: $1,698 · 2021: $2,064 · 2022: $2,115 · 2023: $2,434 · 2024: $2,876 · 2025: $2,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,742 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,741.60 |
| Education | $172.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,016.26 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $1,577.59 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,362.26 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $1,154.37 | 2019-2024 | Spravato, Xarelto |
| Abbvie INC. | $1,062.88 | 2019-2025 | |
| Amgen INC. | $976.85 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $818.17 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $546.71 | 2019-2025 | Freestyle Libre 3, Thoratec Heartmate 3 Lvas Implant Kit, Proclaim |
| Takeda Pharmaceuticals U.S.A., INC. | $474.01 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $450.02 | 2019-2025 | Xifaxan, Trulance, Cycloset |
| Otsuka America Pharmaceutical, INC. | $394.06 | 2021-2025 | Rexulti |
| Glaxosmithkline, LLC. | $365.08 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $334.41 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.25 | 2019-2025 | Jardiance, Synjardy, Glyxambi |
| Cleerly, INC. | $314.02 | 2024-2025 | Cleerly Ischemia, Cleerly Labs |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $309.93 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abiomed | $301.92 | 2024-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $278.85 | 2019-2023 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $191.74 | 2019-2022 | |
| Viiv Healthcare Company | $188.76 | 2024-2025 | Apretude |
| Astellas Pharma US INC | $177.96 | 2019-2024 | Veozah |
| Corium, LLC | $176.71 | 2022-2023 | Azstarys |
| Axsome Therapeutics, INC. | $172.25 | 2024-2025 | Auvelity, Symbravo |
| Dexcom, INC. | $154.97 | 2020-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Idorsia Pharmaceuticals US INC | $151.11 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $128.52 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $125.43 | 2019-2025 | |
| Optinose US, INC. | $112.38 | 2022-2024 | |
| Seqirus USA INC | $111.34 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Biohaven Pharmaceutical Holding Company LTD. | $107.26 | 2022 | |
| Genentech USA, INC. | $92.47 | 2019-2022 | |
| Aytu Biopharma, INC. | $90.44 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $89.56 | 2022-2024 | |
| Biohaven Pharmaceuticals, INC. | $88.83 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $82.74 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $74.29 | 2019-2023 | Qelbree |
| Ardelyx, INC. | $74.14 | 2025 | Ibsrela |
| Vbi Vaccine (Delaware) INC. | $69.45 | 2022 | |
| Ironwood Pharmaceuticals, INC | $68.56 | 2019-2023 | Linzess |
| Indivior INC. | $64.07 | 2024-2025 | Sublocade |
| Sanofi Pasteur INC. | $57.99 | 2019-2025 | |
| Noven Therapeutics, LLC | $53.15 | 2023-2024 | Secuado, Xelstrym |
| Madrigal Pharmaceuticals | $48.74 | 2025 | Rezdiffra |
| Servier Pharmaceuticals LLC | $46.79 | 2024 | |
| Gilead Sciences, INC. | $40.52 | 2025 | Epclusa |
| Bayer Healthcare Pharmaceuticals INC. | $38.64 | 2021-2025 | |
| Cardiovascular Systems INC. | $37.58 | 2019-2020 | |
| Esperion Therapeutics, INC. | $37.08 | 2024 | Nexletol |
| Sumitomo Pharma America, INC. | $36.03 | 2023 | Gemtesa |
| Arbor Pharmaceuticals, INC. | $35.79 | 2019 | |
| Xeris Pharmaceuticals, INC. | $34.46 | 2022-2024 | Keveyis |
| Sunovion Pharmaceuticals INC. | $33.80 | 2022 | |
| Hologic Sales and Service, LLC | $33.77 | 2025 | Aptima |
| Horizon Therapeutics Plc | $33.14 | 2022 | |
| Coloplast Corp | $31.12 | 2019 | |
| Verity Pharmaceuticals INC. | $29.56 | 2024 | Tlando |
| Eisai INC. | $26.53 | 2019 | |
| Almatica Pharma LLC | $26.42 | 2021 | |
| Heartflow, INC. | $26.08 | 2025 | |
| Boston Scientific Corporation | $25.54 | 2024 | Lux-Dx Insertable Cardiac Monitor |
| Jazz Pharmaceuticals INC. | $25.02 | 2019-2020 | |
| Inari Medical, INC. | $24.31 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Stryker Corporation | $21.52 | 2024 | Mako |
| Dynavax Technologies Corporation | $20.38 | 2023 | Heplisav-B |
| Becton, Dickinson and Company | $18.58 | 2021 | |
| Philips North America LLC | $18.40 | 2024 | (Ck7) Extended Holter |
| Daiichi Sankyo INC. | $17.73 | 2021 | |
| Acerus Pharmaceuticals Corporation | $17.04 | 2022 | |
| Biocryst US Sales Co., LLC | $16.38 | 2021 | |
| Mdd US Operations, LLC | $14.18 | 2019 | |
| Optos, INC. | $12.87 | 2020 | |
| Currax Pharmaceuticals LLC | $12.61 | 2020 | |
| Organon LLC | $3.29 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tri Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.